|
|
Legal status
Patent in force
| (51) | INT.CL. | C07D 303/36 | (2006.01) |
| C01G 45/00 | (2006.01) |
| (11) | Number of the document | 3494108 |
| (13) | Kind of document | T |
| (96) | European patent application number | 17751954.3 |
| Date of filing the European patent application | 2017-08-03 | |
| (97) | Date of publication of the European application | 2019-06-12 |
| (45) | Date of publication and mention of the grant of the patent | 2020-10-28 |
| (46) | Date of publication of the claims translation | 2021-01-25 |
| (86) | Number | PCT/US2017/045274 |
| Date | 2017-08-03 |
| (87) | Number | WO 2018/027021 |
| Date | 2018-02-08 |
| (30) | Number | Date | Country code |
| 201662371686 P | 2016-08-05 | US | |
| 201762536862 P | 2017-07-25 | US |
| (72) |
BEAVER, Matthew, US
CUI, Sheng, US
SHI, Xianqing, US
|
| (73) |
Amgen Inc.,
One Amgen Center Drive, Thousand Oaks, California 91320,
US
|
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | (S)-2-amino-4-metil-1-((R)-2-metiloksiran-2-il)-pentan-1-ono sintezė ir jo farmaciniu požiūriu priimtina druska |
| SYNTHESIS OF (S)-2-AMINO-4-METHYL-1-((R)-2-METHYLOXIRANE-2-YL)-PENTAN-1-ONE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF |
| Payment date | Validity (years) | Amount | |
| 2025-07-23 | 9 | 208.00 EUR |
| 2026-08-03 |